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Toxic anterior segment syndrome (TASS) developed in four cases after uneventful implantation of a foldable iris-ﬁxated phakic
intraocular lens (pIOL). Two cases occurred sequentially in one patient. The TASS subsided without complications in all cases
after intensive topical steroid treatment. A multitude of possible causes is considered for the occurrence of these TASS cases. From
the sterilization and cleaning of surgical instruments to the possibility of endotoxines in ophthalmic viscosurgical devices (OVD).
These rare cases should alert the surgeon to the possibility of TASS after pIOL implantation.
1.Introduction
Toxic anterior segment syndrome (TASS) is an acute,
sterile anterior segment inﬂammation following any anterior
segmentsurgicalprocedure[1].Usuallytheanteriorsegment
inﬂammation starts within 12–48 hours after surgery. Clin-
ically alarming symptoms include diminished visual acuity,
increased intraocular pressure, cornealedema,inﬂammation
of the anterior chamber, ﬁbrin, hypopyon, and a ﬁxed
pupil [2–4]. TASS results from a noninfectious toxic agent
within the anterior chamber [5, 6]. The oﬀending substances
includedenatured ophthalmic viscosurgical devices(OVDs),
preservatives, talc from surgical gloves, topical ophthalmic
ointment,inappropriatelyreconstitutedintraocularprepara-
tions, altered pH and osmolarity of intraocular ﬂuids, heat
stable endotoxins, and detergents [5, 6]. Mild to moderate
cases respond well to corticosteroids [3, 4], while severe
cases might lead to corneal decompensation, glaucoma, a
permanently dilated pupil, and cystoid macular edema [2,
3, 7, 8]. TASS is most commonly reported after cataract
surgery and rarely after phakic intraocular lens (pIOL)
implantation [1, 9, 10]. In the literature, three TASS cases
have been reported after pIOL implantation [11, 12]. This
report presents three cases of TASS, two of which occurred
sequentially in one patient after foldable Artiﬂex iris-ﬁxated
pIOL implantation.
2.Case Reports
Case 1. A 45-year-old woman with high myopia consulted
our clinic for a refractive surgical procedure. The patient
was not contact lens intolerant. History revealed no allergy,
uveitis, rheumatic disease, or herpetic keratitis. Corrected
distance visual acuity (CDV) in the right and left eye was,
respectively, 1.0 and 0.80 with a manifest refraction of,
respectively, −12.25 and −15.0–0.50×135. Photopic (85
candelas/m2) low contrast (2.5%) visual acuity (LCVA)
preoperatively was 0.40 and 0.32 in the right and left eye,
respectively. Mesopic(0.7candelas/m2)LCVA preoperatively
was 0.25 and 0.20 in the right and left eye respectively.
Mesopic pupil diameter was 7mm in both eyes (Colvard,
Oasis Medical). Higher-order aberration (HOA) value for a
6mmpupildiameterwas0.44µmintherighteye.Measuring
the HOA for the left eye was out of limit for the Zywave
II aberrometer (Bausch & Lomb). Tonometry measured
16 and 15mmHg, respectively, in the right and left eye.
Preoperative central endothelial cell density (cECD) was
2894 and 2822cells/mm2 in the right and left eye (SP 2000P,
Topcon Inc.). The thinnest corneal thickness was 526µm
and 525µmi nt h er i g h ta n dl e f te y e( O r b s c a nI I z ,B a u s c h&
Lomb).Anteriorchamberdepthwas3.39and3.33mminthe
rightandlefteye.Slitlampexaminationandfundoscopywere
unremarkable. The procedure of choice was implantation of2 Journal of Ophthalmology
Figure 1:Toxicanterior segmentsyndrome(TASS)intheright eye,
one day after implantationof a foldable Artiﬂex pIOL.
afoldableArtiﬂex iris-ﬁxated pIOL(OphtecInc.,Groningen,
The Netherlands) in both eyes. At least two weeks before
surgery, a YAG laser peripheral iridectomy was performed in
both eyes.
Preoperatively, the patient was treated with 1 drop of
pilocarpine nitrate 2% preservative-free (Chauvin Phar-
maceuticals Ltd., UK), oxybuprocaine hydrochloride 0.4%
preservative-free (Chauvin Pharmaceuticals Ltd., UK) and
tetracaine hydrochloride 1% preservative-free eyedrops
(Chauvin Pharmaceuticals Ltd., UK). Three doses (∼40µL
perdose)of each eyedropwere instilled on the ocularsurface
10minapart starting 30minbeforesurgery. One hourbefore
surgery she received diazepam 5mgr po. The periocular skin
and conjunctiva (cul-de-sac) were cleansed with povidone-
iodine 10% (active iodine 1% (Fresenius Kabi, The Nether-
lands)) solution at least 3 minutes before surgery. Lint-
free gloves were used under topical anesthesia. To maintain
pupil constriction intraoperatively, acetylcholine chloride
(Miochol, Thea Pharma) was used.
T h er i g h te y ew a st h eﬁ r s tt ob eo p e r a t e d .F i r s tt w o
vertical paracenteses were performed located at 2 and 10
o’clock and directed to the enclavation site. Intracameral
viscoelastic material (Provisc, Alcon Laboratories, Inc., Fort
Worth, Tex, USA) was introduced. After a corneoscleral
incision of 3.2mm located at 12o’clock, the foldable Artiﬂex
lens was inserted with the use of a specially designed spatula
that allows the surgeon to fold and insert the lens. Special
curved forceps were used for the enclavation by holding
the PMMA haptics at the base. After careful removal of
the Provisc from the anterior chamber with a disposable
irrigating cannula, balanced salt solution (BSS PLUS, Alcon
Laboratories, Inc., Fort Worth, Texas, USA)was injected into
the eye. Thereafter cefuroxime 1.0mg (Zinacef (GlaxoSmith
Kline)) was injected intracamerally to prevent endoph-
thalmitis [13]. Suturing was not necessary since the incisions
were checked watertight. There were no intraoperative
complications. After the operation, prednisone 1% (Pred-
Forte (Allergan)) and ketorolac tromethamine 0.5% (Acular
Allergan) drops were used four times a day. Oﬂoxacin 0.3%
(Traﬂoxal (Tramedico)) drops four times a day were given
for one week. The patient received acetazolamide (Diamox
(Goldshield Pharmaceuticals)) 250mgr orally.
On the ﬁrst postoperative day, the patient presented with
a bruised feeling in the right eye and CDVA of 0.80. The
patienthadnopain.There was conjunctivaland ciliaryinjec-
tion, without evident corneal edema. Slitlamp examination
oftheanteriorchamberrevealeddiﬀusedescemetmembrane
keratic precipitates (KPs), 2+ immobile cells and ﬂare with a
round and sluggishly reactive pupil.There was some ﬁbrinin
theanteriorchamberbutnohypopyon(Figure 1) There were
no cells in the vitreous. The intraocular pressure (IOP) was
18mmHg. Topical prednisone 1% (Pred, Forte) one drop
every hour, ultracortenol ointment (Novartis Pharma) for
the night, and ketorolac tromethamine 0.5% (Acular) four
times daily were prescribed. The patient was under close
followup everyday until afterone week theanterior chamber
reaction subsided, and the conjunctival injection was gone.
There were no KPs or synechiae and the IOP was 13mmHg.
Fundoscopy was unremarkable. CDVA in the right eye was
1.2 with manifest refraction 0–0.50×102. Topical steroids
were tapered. After an extensive discussion with the patient
about the TASS syndrome, the various options and the
risks of pIOL implantation in the fellow eye, a decision was
made to implant an Artiﬂex pIOL without the application of
cefuroxime intracamerally.
Two weeks after the ﬁrst procedure an Artiﬂex pIOL
was implanted in the left eye as described before, without
the injection of cefuroxime intracamerally. There were no
intraoperative complications.
On postoperative day 1, CDVA in the left eye was
0.80 with −1.0–0.50×130. The patient had photophobia
without pain. Slitlamp examination revealed conjunctival
and ciliary injection without corneal edema. There was
an anterior chamber inﬂammation with 1+ immobile cells
and ﬂare, slight ﬁbrin without hypopyon. The pupil was
round with slightly reduced reaction. No cells were apparent
in the vitreous, and fundoscopy was normal. The patient
was prescribed prednisone 1% (Pred Forte) one drop every
hour, ultracortenol ointment (Novartis Pharma) for the
night, and ketorolactromethamine 0.5% (Acular)four times
daily until the anterior chamber reaction subsided. Six days
postoperatively CDVA was 0.90 with −1.0–0.50×130 in the
left eye. There were no cells in the anterior chamber, and
there was some pigment on the pIOL. IOP was 19mmHg.
Slitlamp examination three months postoperatively showed
some cell deposits on the posterior surface of both pIOLs
(Figure 2).
HOA value was 0.45 and 0.27µmi nt h er i g h ta n dl e f t
eye, respectively. Six months postoperatively, CDVA was 1.2
with 0–0.25×100 and 1.2 with −1.25 0 in the right and left
eye,respectively.MesopicandphotopicLCVAwere both0.40
and 0.70/0.50 in the right and left eye, respectively. cECD
was 2688 cells/mm2 and 2909cells/mm2 in the right and
left eye, respectively. Evaluation of the video recording of
both procedures revealed no abnormalities. The duration of
surgery was approximately 10 and 7 minutes in the right and
left eye, respectively.
Skin patch tests with cefuroxime, Provisc, and Mio-
chol revealed no reactions. There was a 1+ (erythema
with papules or induration) skin patch reaction with N-
isopropyl-N -phenyl-paraphenylenediamine (IPPD)(rubberJournal of Ophthalmology 3
Figure2:CelldepositsontheposteriorsurfaceofafoldableArtiﬂex
phakic pIOL in the right eye, two months after surgery. The TASS
has subsides.
antioxidant),nickelsulphate5%,mercaptobenzothiazole2%
(rubber accelerator), sesquiterpene lactone mix 0.1%, and
tixocortol-21-pivalate 1%.
Case 2. A 33-year-old woman received bilateral toric Arti-
ﬂex pIOL implantation for the correction of her myopia
and astigmatism. History was unremarkable. CDV in the
right and left eye was, respectively, 0.70 and 0.90 with
a manifest refraction of, respectively, −8.00–2.50×5a n d
−6.50–2.25×169. Photopic LCVA preoperatively was 0.25
and 0.30 in the right and left eye, respectively. Mesopic
LCVA preoperatively was 0.25 and 0.30 in the right and
left eye, respectively. HOA value for a 6mm pupil diameter
was 0.37µmi nt h er i g h te y ea n d0 . 4 4 µmi nt h el e f te y e .
Tonometry measured 12 and 10mmHg, respectively, in
the right and left eye. Preoperative cECD was 3184 and
2860cells/mm2 in the right and left eye. Anterior chamber
depth was 3.52 and 3.58mm in the right and left eye. White-
to-white was 11.6mm in both eyes. Slitlamp examination
andfundoscopywereunremarkable.Theprocedureofchoice
was implantation of afoldabletoricArtiﬂex iris-ﬁxated pIOL
(Ophtec Inc., Groningen, The Netherlands) in both eyes.
Ap I O Lo f−8.50 D −2.0×0a n d−7.00 D −2.0×0w a s
implanted in axis 5 and 169 of, respectively, the right and left
eye. The preoperative preparation and pIOL implantation
in both eyes was performed as described in Case 1.B o t h
eyes received cefuroxime intracamerally. The right eye was
operated ﬁrst. One day postoperatively, the patient had
blurred vision without pain. There was ciliary injection
with no evident corneal edema. Slitlamp examination of the
anterior chamber revealed diﬀuse descemet membrane KPs,
2+ immobile cells and ﬂare with a round and sluggishly
reactive pupil. There was extensive ﬁbrin in the anterior
chamber with a hypopyon (Figure 3).
There were no cells in the vitreous. The intraocular
pressure (IOP) was 9mmHg. Intensive topical steroid treat-
ment was administered until the anterior chamber reaction
subsided. Four days postoperatively, there were no KPs or
ﬁbrin in the anterior chamber (Figure 4), and the IOP was
11mmHg.
Figure3:SevereﬁbrinousreactiononedayafterfoldabletoricpIOL
implantation in the anterior chamber.
Figure 4: Pigment deposits on the posterior surface of a foldable
toric Artiﬂex pIOL one week after surgery.
Fundoscopy was unremarkable. CDVA was 1.0 with
0–0.50×110. Topical steroids were tapered. The left eye
subsequently received a foldable toric Artiﬂex pIOL with a
peroperativeirisprolaps,which wasrepositioned.Therewere
no postoperative complications. Six months postoperatively
CDVA was 1.0 with 0.75-0.75×110 and 1.2 with 0–0.75×55
in the right and left eye, respectively. Mesopic and photopic
LCVA were both 0.32 and 0.40 in the right and left eye,
respectively. HOA value for a 6mm pupil diameter was
0.53µmi nt h er i g h te y ea n d0 . 3 9µmi nt h el e f te y e .c E C D
was 3088cells/mm2 and 2916cells/mm2 in the right and left
eye, respectively.
3.Discussion
Toxic anterior segment syndrome (TASS) is a potentially
devastating acute inﬂammatory reaction in the anterior
chamber and is increasing in recognition [1, 11, 12, 14–
16]. It is most commonly reported after cataract surgery, but
has been also reported after pIOL implantation, penetrating
keratoplasty and intravitreal injection with bevacizumab [1,
11, 12, 14, 16–18]. TASS should be diﬀerentiated from post-
operative endophthalmitis. Clinically TASS is characterized
by intense early postoperative inﬂammation of the anterior
segment, ﬁbrin formation, and corneal edema [1, 14, 16].
Patients with TASS usually do not have perocular pain, and4 Journal of Ophthalmology
there is rarely any vitreous inﬂammation. The TASS cases
presented in this report had minimal decrease in CDVA with
intense anterior chamber inﬂammation, ﬁbrin formation,
and hypopyon. There was no increased intraocular pressure,
corneal edema, or vitritis. The cases occurred within 24
hours after iris-ﬁxated pIOL implantation and responded
well to intense steroidal treatment, which is typical for
TASS, diﬀerentiating it from endophthalmitis. Hence taking
culturesamplesfrom theaqueoushumororvitreous was not
necessary. Moshirfar et al. reported a case of TASS after rigid
iris-ﬁxated pIOL (Verisyse) implantation with severe corneal
edema, which resolved over a period of 2 months with
steroidal treatment [12]. After one year corneal endothelial
cell density had decreased by 69%. The authors attributed
the endothelial cell loss to a toxic insult consistent with
TASS. A deﬁnite toxic substance was not identiﬁed. Another
study reported two cases with TASS,one after rigid (Verisyse,
AMO, Abbott Park Ill, Usa) and one after foldable (Artiﬂex,
Ophtec BV, The Netherlands) iris-ﬁxated pIOL implanta-
tion, with severe ﬁbrinous anterior chamber inﬂammation,
hypopyon, and nonsigniﬁcant corneal edema [11]. Anterior
chamber washout and aspiration of ﬁbrin membranes were
performed. Intracamerally ceftazidimeandvancomycin were
injected. Cefazolin and garamycin drops were instilled until
anteriorchamber ﬂuidcultureswere negative.Afterintensive
steroidal treatment the TASS subsided in both cases within
one week. The authors suggested that Multivisc BD was the
toxic agent causing TASS [11].
Numerous noninfectious substances have been impli-
cated to cause TASS: abnormal pH and osmolarity, anes-
thetic agents, preservatives, intraocular lenses, irritants on
the surfaces of surgical instruments (denatured OVDs),
heat stable endotoxins, impurities of autoclave steam,
and topical ophthalmic ointments [5, 6]. The multi-
tude of possible causes of TASS makes it diﬃcult to
prevent. The TASS task force of the American Soci-
ety of Cataract and Refractive Surgery (ASCRS) has
developed a questionnaire to assist investigation of a
TASS outbreak (http://www.ascrs.org/TASS/Instrument-Re-
processing-Product-Questionnaire-Survey.cfm). Two of the
three TASS cases presented in this study occurred in the
same patient and sequentially. The three cases probably do
not constitute an outbreak. There were no other cases of
TASS at the surgical center in the same period. The surgical
instruments used in both cases were either disposable
(syringes, enclavation needle, and cannulas) or nondispos-
able (titanium spatula and forceps) and were rinsed and
sterilized according to a strict protocol. Surgical instrument
cleaning and sterilization cannot be ruled out as the cause of
these TASS cases. After the ﬁrst TASS case cefuroxime was
considered a possible toxic or allergic agent, even though
previous surgeries had no toxic outcome. Thus in the fellow
e y ec e f u r o x i m ew a sn o tu s e d .T om i n i m i z et h er i s ko fd o s a g e
errors the intracameral cefuroxime, for the ﬁrst eye, was
prepared in the hospital pharmacy and not in the operating
theatre. Though cefuroxime seems safe touse intracamerally,
in patients with vulnerable corneal endothelial cells, it may
be more toxic [19]. The sequential TASS in the fellow eye
of Case 1 in this paper probably rules out cefuroxime as
a cause. Miochol could not be ruled out as a cause, but
no correlation with TASS has been reported. The pIOL
design and compound (polymethyl methacrylate (PMMA)
haptics and silicone optic) were also considered as potential
causes of TASS. The lot numbers of both Artiﬂex lenses were
diﬀerent. It has been reported that after foldable Artiﬂex
pIOL implantation giant cells with pseudopodia adhere to
the posterior surface of the lens and that 4.8% develops
pigment deposits on the pIOL [19, 20]. Whether these rare
long-term complications indicate a predisposition to TASS
development remains unclear. Two TASS cases in this report
developed some cell deposits on the posterior surface of the
pIOL. The third case had some pigment precipitates on the
pIOL. Although possible, it is unlikely that povidone iodine
entered the anterior chamber, since the concentration used
in both eyes would have been highly toxic to the corneal
endothelium and no corneal edema was noted [21, 22].
The Provisc used in these cases did not contain dry natural
rubber, which is another potential cause of TASS [5, 6].
Viscosurgical devices can be produced by gene-coded
bacteria in a microbial fermentation process and may be
contaminated by heat stable endotoxins [11]. Endotoxins in
OVDs must not exceed 0.50 endotoxin units/mL [23]. The
highest acceptable endotoxin concentration (EC), however,
isyet tobeestablished.Inonestudy,Provisc hadanECunder
1.2 endotoxin units/mL [24]. Concern has been expressed
regarding the presence of endotoxins in OVDs, which may
be responsible for postoperative anterior chamber reactions
[11, 25]. The use of pure OVDs is therefore recommended to
prevent inﬂammatory reactions [24].
The unique sequential TASS development in both eyes
of one patient, presented in this paper, suggests a unique
reaction to a noninfectious substance. One hypothesis might
be that heat-stable endotoxins in the Provisc caused an
anterior segment inﬂammatory reaction in a hypersensitive
patient. Implantation of a foldable iris-ﬁxated pIOL carries a
risk of viscosurgical remnants in the eye; therefore, thorough
irrigation at the close of surgery is recommended. This
paper serves to alert surgeons to the possibility of TASS after
implantation of a foldable iris-ﬁxated pIOL.
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